This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.
For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.
Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.
On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.
Turn Therapeutics Inc. files its annual report describing a dermatology-focused pipeline built around GX-03, a non-systemic topical immunomodulator for moderate-to-severe eczema and onychomycosis, plus an exploratory thermostable intranasal vaccine platform.
The company leverages prior 510(k) device clearances and animal data to run an approximately 114–120 patient randomized, double-blind, vehicle-controlled Phase 2-equivalent eczema trial, with interim analysis at 50% enrollment and topline results expected mid-2026. GX-03 has shown preclinical cytokine inhibition and antifungal nail penetration with favorable tolerability. Turn pursues a capital-light model using contract manufacturers and partners, highlighted by a MiMedx license for the collagen-based FleX Product with up to $69.55 million in potential milestones plus mid-single-digit royalties, and an October 2025 Medline agreement to co-develop and distribute PermaFusion-based wound and personal care products globally.
The report also discloses net losses, an accumulated deficit, and substantial doubt about the company’s ability to continue as a going concern, alongside reliance on external financing, including an up to $85.0 million share purchase facility with GEM and potential future equity dilution.
Turn Therapeutics Inc. reported full year 2025 results and provided clinical and corporate updates. Operating expenses rose to $5.9 million, driven mainly by general and administrative costs, leading to a net loss of $3.2 million compared with $1.8 million in 2024. Other income of $2.7 million, including gains from changes in fair value of a derivative liability instrument and a forward contract liability, partially offset operating losses. Cash and cash equivalents increased to $5.1 million and total assets to $12.2 million, with stockholders’ equity turning positive.
The company highlighted its Phase 2 trial of lead candidate GX-03 for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026. Turn also secured up to $25 million in growth capital from Avenue Capital Group, which it states is expected to extend its runway through the end of 2027, and referenced a global license, supply, and distribution agreement with Medline that it believes could enable revenue beginning in late 2026.
Turn Therapeutics Inc. entered into a growth capital loan agreement with Avenue Venture Opportunities Fund II for term loans of up to $25.0 million. An initial $7.0 million tranche is funded at closing, with up to $8.0 million in Tranche 2 and a discretionary Tranche 3 of up to $10.0 million tied to clinical and financing milestones and mutual agreement.
The loans bear interest at the greater of prime plus 5.50% or 12.25%, mature on October 1, 2029, and are secured by liens on all company assets, including intellectual property. Turn will make interest-only payments for at least 15 months, with potential extensions based on milestone achievement, followed by amortization to maturity.
As part of the deal, Turn paid a $150,000 commitment fee and agreed to a 3.75% final payment on aggregate funded amounts. The lender can convert up to $2.0 million of principal, rising to $3.0 million if Tranche 2 is funded, into common stock at 80% of the closing share price, and received an equity grant valued at $1.2 million. A participation right allows up to $1.0 million investment in future equity financings. A related press release states the financing is expected to extend Turn’s cash runway through its Phase 2 atopic dermatitis readout and potentially through the end of 2027.
Turn Therapeutics filed a current report to share a press release announcing that Robert Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, has been appointed Senior Advisor of Health Policy and Regulatory Affairs.
Dr. Redfield will advise on clinical development, public health considerations, and regulatory positioning of Turn’s lead investigational therapy, GX-03, which is in Phase 2 clinical trials. GX-03 is described as a first-in-class, non-systemic topical inhibitor in late-stage development for moderate-to-severe atopic dermatitis and other inflammatory dermatologic conditions.
Turn Therapeutics Inc. furnished a press release and updated investor presentation outlining upcoming appearances at the TD Cowen and Oppenheimer healthcare conferences and providing a detailed pipeline update. The company is developing GX-03, a first-in-class, non-systemic topical immunomodulator targeting IL-36, IL-31 and IL-4 for moderate-to-severe eczema, with a Phase 2 randomized controlled trial underway and topline results expected mid-2026.
The presentation highlights additional GX-03 opportunities in onychomycosis and psoriasis, plus a thermostable intranasal vaccine program enabled by the PermaFusion delivery platform. Turn reports raising about $21 million since 2015, cumulative cash burn of about $18 million, expected Phase 3 R&D spending of $55–60 million, and projected public-company G&A costs of about $250,000 per month. Existing device products are out-licensed to Medline and MiMedx with potential milestone payments exceeding $70 million.
Turn Therapeutics Inc. director Martin William Dewhurst received an award of 21,882 restricted stock units (RSUs) of common stock on January 7, 2026 at a price of $0 per unit. Each RSU represents the right to receive one share of common stock.
The 21,882 RSUs vest in full on January 7, 2027, provided Dewhurst continues to serve the company through that date. The award was made under Turn Therapeutics’ 2025 Omnibus Incentive Plan and is held directly by the reporting person.
Turn Therapeutics Inc. director Martin William Dewhurst filed an initial ownership report showing a stock option to buy 40,030 shares of common stock at an exercise price of $4.59 per share. The option became exercisable for 10,000 shares on July 26, 2024 and for 858 shares on the last day of each month thereafter, reflecting a 2-for-1 stock split that took effect on September 30, 2025. The option expires on July 26, 2034 and is held directly.
Turn Therapeutics Inc. filed a current report to furnish a company press release under Item 7.01 (Regulation FD Disclosure). The report notes that the press release, dated January 12, 2026 and attached as Exhibit 99.1, is being treated as information that is "furnished" rather than "filed" for purposes of the Securities Exchange Act of 1934. This means it is not subject to the liability provisions of Section 18 unless the company later specifically incorporates it by reference into a Securities Act or Exchange Act filing.
Turn Therapeutics Inc. expanded its board of directors from five to six members and appointed Martin Dewhurst as an independent Class III director, effective January 7, 2026. He will serve until the 2028 annual stockholders’ meeting, unless he leaves earlier, and will chair the board’s compensation committee.
Dewhurst brings more than 30 years of global life sciences leadership, including senior advisory roles at GHO Capital, PJT Partners, and LightRock, and prior experience as a senior partner at McKinsey & Co. In connection with his appointment, he received restricted stock units with a grant-date fair value of $100,000 under the 2025 Omnibus Incentive Plan, vesting on the first anniversary of the grant or upon a change of control, whichever occurs first. After the first anniversary of the company’s direct listing effective date, he will be eligible for an annual RSU grant with a grant-date fair value of $70,000. The company also furnished a press release and an updated investor presentation dated January 7, 2026.
Turn Therapeutics Inc. reported an insider stock purchase by officer Zuraiz Chaudhary. On 12/12/2025, Chaudhary bought 2,500 shares of common stock at $3.5 per share, bringing their directly held beneficial ownership to 12,500 shares.
Chaudhary serves as Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer, and this report covers a single reporting person with direct ownership of the common stock.